Safety Information
| Description | Publish Date | LINKS |
|---|---|---|
| Important safety information on Dolutegravir in Uganda |
10/10/2018 |
 |
| Important safety information on Abacavir: Hypersensitivity reaction - educational slide deck | 15/02/2024 | |
| Important safety information on SSRIs and SNRIs containing products in Uganda | 03/02/2021 | |
| Important safety information on Ceruroxime sodium in Uganda (Safety Notification_Cefuroxime Class 4 Defect MHRA) | 30/10/2023 | |
| Important safety information on Dolutegravir in Uganda (Safety Notification_Korean label update for Dolutegravir containing products) | 01/11/2023 | |
| Important safety information on Cephalosporins in Uganda (Safety Notification_Cephalosporins and risk of seizure) | 01/03/2023 | |
Important safety information on Cephalosporins in Uganda (Safety Notification_Cephalosporins and risk of neurotoxicity) |
07/03/2023 |
|
Important safety information on Amoxicillin / Amoxicillin and clavulanic acid containing products in Uganda |
09/09/2023 | |
| Important safety information on Hepatitis B surface antigen recombinant vaccine in Uganda (Initial Safety Notification Engerix-B and Myelitis_November 2023) | 17-11-2023 | |
| Important safety information on Hepatitis B surface antigen recombinant vaccine in Uganda (Updated Safety Notification Engerix-B and Myelitis_December 2023) | 02-01-2024 | |
Important safety information on Hepatitis B surface antigen recombinant vaccine (Updated Safety Notification Engerix-B and Myelitis_January 2024) |
08/01/2024 |
|
Important safety information on Abacavir containing products - Regarding amendments to the instructions for medical use of medicines containing abacavir |
19/03/2024 |
|
Important safety information on Hepatitis B surface antigen recombinant vaccine - Updated Safety Notification Engerix-B and Myelitis_May 2024 |
07/05/2024 |
|
